A recent follow-up data in relapsed and/or refractory acute lymphoblastic leukemia (ALL) patients suggest development of a common disease resistance mechanism, including downregulation/loss of CD19 antigen in 30–70% of patients who have recurrent disease after treatment [31]. The gene discussed is CD19; the disease is acute lymphoblastic leukemia.